Latest news with #PMNDP
New Indian Express
12 hours ago
- Health
- New Indian Express
Aadhaar now must for dialysis scheme benefits in Karnataka
BENGALURU: The state government has issued a notification mandating Aadhaar authentication for availing benefits under the Pradhan Mantri National Dialysis Programme (PMNDP), implemented through the Suvarna Arogya Suraksha Trust. This is to ensure better service delivery, transparency, and to ensure entitlements are distributed efficiently. According to the Department of Personnel and Administrative Reforms (DPAR), both Priority Household (PHH) and non-PHH ration card holders must either furnish proof of Aadhaar or undergo Aadhaar authentication to avail the benefits. However, the government clarified that no individual, adult or child will be denied treatment for lack of Aadhaar. In such cases, other identity documents will be accepted, and a register will be maintained to track these for audit and review purposes. Aadhaar enrolment facilities will be set up at block or taluk levels where centres are currently unavailable. In cases where biometric authentication fails, due to poor fingerprint quality or other issues, the department has recommended alternatives such as iris or face scans, OTP-based authentication, or physical Aadhaar letters validated through QR code scanners.
Time of India
4 days ago
- Business
- Time of India
Renalyx launches India's first indigenous AI based smart hemodialysis machine, makes renal care accessible and affordable
Renalyx dignitaries with AI based smart hemodialysis machine MUMBAI: Renalyx Health Systems Pvt. Ltd., a pioneering technology innovation company in renal care, has launched RENALYX – RxT 21, India's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility. Price starting at INR 6.70 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions. According to Pradhan Mantri National Dialysis Program (PMNDP) data, approximately 2.2 lakh new cases of End-Stage Renal Disease (ESRD) are reported in India each year, creating an additional demand for 3.4 crore dialysis sessions annually Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues. RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification. Renalyx has plans to invest INR 800 crores in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand. The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years. With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe. Commenting on the launch of Rx T21, Dr. Shyam Vasudeva Rao, Founder & Director of Renalyx Health Systems said, 'Our cutting-edge hemodialysis machine will revolutionise the renal care by making dialysis facility affordable and accessible, thus strengthening the kidney healthcare infrastructure of the country. By bringing dialysis services closer to patients' homes, RxT 21 will help in addressing the rising Chronic Kidney Disease (CKD) burden and ESRD patients. Our indigenously developed hemodialysis machine will play a game-changing role in reducing dialysis expense, thus ensuring better healthcare impact. Going forward, we have plans to scale up our manufacturing capacity and reduce the Total Cost of Ownership of RxT 21 by 40% compared to that of imported machines. We have plans to develop a broader range of technologically advanced machines over the next three years, including a home dialysis model. In line with the government vision of 'Make in India Make for the World', we aim to export our machine to various countries to make a larger impact on renal care infrastructure globally. We aim to become one of the world's leading producers and exporters within the next five years.' The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the U.S. FDA approval process is underway and anticipated by March 2026. The RENALYX – RxT 21 machines are equipped with advanced features such as Integrated Nephrology Information System (NIS) on the cloud, AI based smart algorithms, Electronic Medical Records (EMR) integration, remote diagnostics and alerts through real-time telemetry, Advanced image processing, Internet of Medical Things (IoMT) capabilities for continuous performance monitoring and clinical oversight. Thanks to these advanced features, doctors can remotely access patients' EMR, current settings of the dialysis machine and patients' critical event history to take action and advise necessary treatment and care. Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. The company has set up local service teams and created technician training programs to ensure smooth roll-out of the smart machines. The company will set up franchisee centres across India along with its partners. The company, in collaboration with its partner, will set up franchise centres across India and in international markets. In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities. With RENALYX – RxT 21 and RxT 17, Renalyx aims to play its role in making dialysis services affordable and accessible to the rural areas due to the recurring nature of the treatment.
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Renalyx launches smart dialysis unit RxT21, plans ₹800 crore boost
Bengaluru-based Renalyx Health Systems has launched a cloud-enabled and AI-powered smart haemodialysis machine with real-time remote monitoring and clinical connectivity. Named RxT21 and priced at ₹6.7 lakh, the machine is claimed to be significantly cheaper than imported alternatives. Comparable models in the market cost 20–25 per cent more, the company said. Renalyx plans to invest ₹800 crore over the next four years to build manufacturing capacity for an initial 5,000 RxT21 machines by FY26, with an additional 1,500-unit capacity by FY28. The company will also manufacture consumables indigenously. Renalyx has manufacturing facilities in Bengaluru and Mysuru in Karnataka and in Mumbai, Maharashtra, to support its scale-up plans and meet rising demand. CDSCO approval for the RxT21 is in its final stages and expected by July 2025, while the USFDA approval process is under way and anticipated by March 2026, the company told Business Standard. Shyam Vasudeva Rao, founder and director of Renalyx Health Systems, said RxT21 would bring dialysis closer to patients' homes, helping reduce dropout rates. Remote monitoring is critical, especially as many rural patients miss their dialysis sessions—typically three per week—due to travel challenges. 'With this machine, we can monitor a patient's vitals during dialysis and stop the process immediately if any issue arises, reducing the need for highly trained manpower at rural centres,' Rao said. According to data from the Pradhan Mantri National Dialysis Programme (PMNDP), approximately 220,000 new cases of end-stage renal disease (ESRD) are reported in India annually, generating demand for 34 million dialysis sessions. Industry estimates suggest the country currently performs 21–22 million sessions annually, supported by 50,000 dialysis machines, 5,000 centres, and about 3,000 practising nephrologists. As the dialysis sector grows, domestic medical device makers are entering the fray. Currently, most dialysis machines in India are imported, with German firm Fresenius leading the market. Industry estimates indicate that 35,000 of the 50,000 machines deployed in India are from Fresenius. These machines typically cost between ₹7–8 lakh, excluding the cost of dialysers (the filtering unit) and other consumables. Founded in 2012, Renalyx also produces the RxT17 dialysis machine, which has standard features. It has licensed Bharat Electronics (BEL) to manufacture 6,000 RxT17 units over the next three years. The company has invested ₹52 crore so far in manufacturing and R&D. 'The company plans to raise funds through equity sales, supported by strong interest from Indian and international investors. In addition, it will raise debt, with promoters also infusing capital. Renalyx intends to go public within the next three years,' it said in a statement. Initial deployments of the RxT21 are planned in Maharashtra and Karnataka. Renalyx will then pursue rapid pan-India distribution of the machine in partnership with domestic collaborators and also export to global markets. The company has already secured orders from South Africa, the United States, and Europe.
Time of India
06-05-2025
- Health
- Time of India
Delhi Govt To Expand Dialysis Services With 150 New Machines At Six Hospitals
New Delhi: Delhi govt is set to expand its healthcare infrastructure by adding 150 new dialysis machines across six govt hospitals. This initiative will provide complimentary dialysis services to economically weaker sections whilst offering subsidised treatment to expansion is being executed through Pradhan Mantri National Dialysis Programme (PMNDP) and PPP Dialysis Project . This development supplements the existing network of 150 machines currently operating under these programmes at 10 govt hospitals."We are proud to lead this effort in Delhi to ensure that life-saving dialysis is not a privilege but a right for every citizen, especially the needy people," said health minister Pankaj Kumar Singh. "No patient should be denied care due to financial hardship."The minister further added, "This is not just a medical service expansion; it is a promise to our people that Delhi govt stands by their side during hardship."The current 150 dialysis machines are functioning at Bhagwan Mahavir Hospital, Guru Gobind Singh Govt Hospital, Indira Gandhi Hospital, Pt Madan Mohan Malaviya Hospital, Deep Chand Bandhu Hospital, Deen Dayal Upadhyay Hospital, Maharishi Valmiki Hospital, Lok Nayak Hospital, Rajiv Gandhi Super Speciality Hospital and Dr Hedgewar Aarogya new installations are occurring at six additional facilities—Dr Baba Saheb Ambedkar Hospital, Jag Pravesh Chandra Hospital, Burari Hospital, Janakpuri Super Specialty Hospital, Ambedkar Nagar Hospital, and Sanjay Gandhi Memorial PMNDP hospitals, patients possessing a National Food Security Card for PR & PRS category or an income certificate showing an annual income below Rs one lakh under the BPL category receive free dialysis PPP model hospitals, Delhi residents with three years of residency and holding either a National Food Security Card or an income certificate showing an annual income up to Rs 3,00,000 qualify for free dialysis.
